News | May 29, 2007

Sickest Heart Patients May Not Get Treatments They Need

May 30, 2007 -- The Canadian Press reports this week that people in the greatest need of cardiac medications and interventions are less likely than moderately ill patients to get the full range of heart drugs and procedures, and it may be because they fail the "eyeball" test.

Two American cardiologists have suggested that doctors may view these patients, the sickest of the sick, as too ill to benefit from invasive treatments like catheterization or too depressed or unwell to deal with the hassle of more medication in what is likely already a multi-pill daily regime.

Dr. John Spertus of the University of Missouri, Kansas City and Dr. Mark Furman of the University of Massachusetts Medical School express their views in an editorial in the "Archives of Internal Medicine."

Their editorial accompanies two studies by Canadian research teams that found that sicker patients were less likely to be getting an important cholesterol lowering drug called a statin or to undergo cardiac catheterization.

The studies add support to what's called the treatment-risk paradox, a phenomenon first described by researchers at Toronto's Institute for Clinical Evaluative Studies.

They reported in 2004 that patients who would benefit most from cardiac interventions were least likely to be getting them.


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now